Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $0.25. Hemispherx BioPharma shares last traded at $0.22, with a volume of 864,053 shares changing hands.
Hemispherx BioPharma Price Performance
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Further Reading
- Five stocks we like better than Hemispherx BioPharma
- What is Forex and How Does it Work?
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Using the MarketBeat Stock Split Calculator
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- Stock Market Sectors: What Are They and How Many Are There?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
